Compass Therapeutics, Inc. $CMPX Shares Purchased by Sofinnova Investments Inc.

Sofinnova Investments Inc. boosted its position in Compass Therapeutics, Inc. (NASDAQ:CMPX) by 65.9% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,365,446 shares of the company’s stock after buying an additional 1,336,560 shares during the quarter. Sofinnova Investments Inc.’s holdings in Compass Therapeutics were worth $18,072,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in the company. LPL Financial LLC lifted its holdings in Compass Therapeutics by 4.7% in the 4th quarter. LPL Financial LLC now owns 44,470 shares of the company’s stock worth $239,000 after buying an additional 2,000 shares in the last quarter. Victory Capital Management Inc. lifted its holdings in Compass Therapeutics by 20.6% in the 3rd quarter. Victory Capital Management Inc. now owns 12,652 shares of the company’s stock worth $44,000 after buying an additional 2,164 shares in the last quarter. Focus Partners Wealth lifted its holdings in Compass Therapeutics by 16.2% in the 3rd quarter. Focus Partners Wealth now owns 15,805 shares of the company’s stock worth $56,000 after buying an additional 2,206 shares in the last quarter. Dimensional Fund Advisors LP lifted its holdings in Compass Therapeutics by 1.9% in the 3rd quarter. Dimensional Fund Advisors LP now owns 175,556 shares of the company’s stock worth $619,000 after buying an additional 3,329 shares in the last quarter. Finally, Welch & Forbes LLC lifted its holdings in Compass Therapeutics by 26.7% in the 4th quarter. Welch & Forbes LLC now owns 19,000 shares of the company’s stock worth $102,000 after buying an additional 4,000 shares in the last quarter. Institutional investors and hedge funds own 68.43% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Compass Therapeutics in a report on Monday, April 20th. Citizens Jmp reiterated a “market outperform” rating and issued a $10.00 price objective on shares of Compass Therapeutics in a report on Tuesday, April 28th. Guggenheim reiterated a “buy” rating and issued a $12.00 price objective on shares of Compass Therapeutics in a report on Tuesday, March 24th. Canaccord Genuity Group cut their price objective on shares of Compass Therapeutics from $13.00 to $7.00 and set a “buy” rating on the stock in a report on Tuesday, April 28th. Finally, William Blair reiterated an “outperform” rating on shares of Compass Therapeutics in a report on Thursday, March 5th. One investment analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $12.91.

Compass Therapeutics Stock Performance

Shares of Compass Therapeutics stock opened at $2.04 on Tuesday. The firm has a market cap of $367.38 million, a PE ratio of -4.98 and a beta of 0.89. The firm’s 50-day simple moving average is $3.10 and its 200-day simple moving average is $4.74. Compass Therapeutics, Inc. has a 1 year low of $1.61 and a 1 year high of $6.88.

Compass Therapeutics (NASDAQ:CMPX) last issued its earnings results on Tuesday, May 5th. The company reported ($0.10) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.10). On average, equities analysts predict that Compass Therapeutics, Inc. will post -0.42 earnings per share for the current year.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company’s lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don’t eat me” signals on cancer cells.